Adnexal mass: diagnosis and management

Key points

• Adnexal masses occurred in women of all age groups, and their etiology and frequency vary age accordingly.

• Most of the adnexal masses are benign, without symptoms diagnosed incidentally, and can have expectant management.

• Otherwise, ovarian cancer is an adnexal mass with poor prognosis and must be managed quickly in an appropriate setting.

• Correct differential diagnoses of benign and malignant mass matter.

• Panels of biomarkers is not sufficient for the initial evaluation of an adnexal mass.

• Transvaginal ultrasonography is the single most effective way of evaluating an ovarian mass.

• Ovarian cancer patients referred to a cancer center for further Management experience the best outcomes.

The National Specialized Commission on Gynecologic Oncology of the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO) endorses to this document. The content production is based on scientific studies on a thematic proposal and the findings presented contribute to clinical practice.

• References

• 1 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology. Practice Bulletin No. 174: evaluation and management of adnexal masses. Obstet Gynecol 2016; 128 (05) e210-e226 . Doi: 10.1097/AOG.0000000000001768
• 2 Lima RA, Viotti LV, Cândido EB, Silva-Filho FL. Abordagem das massas anexiais com suspeita de câncer de ovário. Femina 2010; 38 (06) 259-262
• 3 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Ovarian Cancer including fallopian tube cancer and primary peritoneal cancer [Internet]. Version 1.2020. 2010 [cited 2020 Mar 11]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#ovarian
• 4 Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO. Centralisation of services for gynaecological cancers - a Cochrane systematic review. Gynecol Oncol 2012; 126 (02) 286-290 . Doi: 10.1016/j.ygyno.2012.04.012
• 5 Royal College of Obstetricians and Gynaecologists. The management ovarian cysts in postmenopausal women. London: RCOG; 2016
• 6 Royal College of Obstetricians and Gynaecologists. Ovarian masses in premenopausal women, management of suspected. London: RCOG; 2011
• 7 American College of Radiology. Don’t recommend follow-up imaging for clinically inconsequential adnexal cysts [Internet]. 2012 [cited 2019 Dec 12]. Available from: https://www.choosingwisely.org/clinician-lists/american-college-radiology-follow-up-imaging-for-adnexal-cysts/
• 8 Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Res Treat 2016; 160 (03) 393-410 . Doi: 10.1007/s10549-016-4003-9
• 9 Ring KL, Garcia C, Thomas MH, Modesitt SC. Current and future role of genetic screening in gynecologic malignancies. Am J Obstet Gynecol 2017; 217 (05) 512-521 . Doi: 10.1016/j.ajog.2017.04.011
• 10 Ebell MH, Culp MB, Radke TJ. A systematic review of symptoms for the diagnosis of ovarian cancer. Am J Prev Med 2016; 50 (03) 384-394 . Doi: 10.1016/j.amepre.2015.09.023
• 11 Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291 (022) 2705-2712 . Doi: 10.1001/jama.291.22.2705
• 12 Dodge JE, Covens AL, Lacchetti C, Elit LM, Le T, Devries-Aboud M. , et al. Management of a suspicious adnexal mass: a clinical practice guideline. Curr Oncol 2012; 19 (04) e244-e257 . Doi: 10.3747/co.19.980
• 13 Timmerman D, Van Calster B, Testa A, Savelli L, Fischerova D, Froyman W. . et al. Predicting the risk of malignancy in adnexal masses based on the simple rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol 2016; 214 (04) 424-437 . Doi: 10.1016/j.ajog.2016.01.007
• 14 Sayasneh A, Ferrara L, De Cock B, Saso S, Al-Memar M, Johnson S. , et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study. Br J Cancer 2016; 115 (05) 542-548 . Doi: 10.1038/bjc.2016.227
• 15 Abramowicz JS, Timmerman D. Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules. Am J Obstet Gynecol 2017; 217 (06) 652-660 . Doi: 10.1016/j.ajog.2017.07.019
• 16 Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276 (029) 27371-27375 . Doi: 10.1074/jbc.M103554200
• 17 Sehouli J, Akdogan Z, Heinze T, Könsgen D, Stengel D, Mustea A. , et al. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Anticancer Res 2003; 23 (2A): 1115-1118
• 18 Jacobs I, Bast Jr. RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4 (01) 1-12 . Doi: 10.1093/oxfordjournals.humrep.a136832
• 19 Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H. , et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100 (08) 1315-1319 . Doi: 10.1038/sj.bjc.6605011
• 20 Anastasi E, Granato T, Falzarano R, Storelli P, Ticino A, Frati L. , et al. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res 2013; 6: 44 . Doi: 10.1186/1757-2215-6-44
• 21 Hallamaa M, Suvitie P, Huhtinen K, Matomäki J, Poutanen M, Perheentupa A. Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women. Gynecol Oncol 2012; 125 (03) 667-672 . Doi: 10.1016/j.ygyno.2012.03.011
• 22 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97 (010) 922-929 . Doi: 10.1111/j.1471-0528.1990.tb02448.x
• 23 Chudecka-Glaz AM. ROMA, an algorithm for ovarian cancer. Clin Chim Acta 2015; 440: 143-151 . Doi: 10.1016/j.cca.2014.11.015
• 24 Anton C, Carvalho FM, Oliveira EI, Maciel GAR, Baracat EC, Carvalho JP. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo) 2012; 67 (05) 437-441 . Doi: 10.6061/clinics/2012(05)06
• 25 Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ. , et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112 (01) 40-46 . Doi: 10.1016/j.ygyno.2008.08.031
• 26 Hermans AJ, Kluivers KB, Janssen LM, Siebers AG, Wijnen MHWA, Bulten J. , et al. Adnexal masses in children, adolescents and women of reproductive age in the Netherlands: a nationwide population-based cohort study. Gynecol Oncol 2016; 143 (01) 93-97 . Doi: 10.1016/j.ygyno.2016.07.096
• 27 Reddihalli PV, Subbian A, Umadevi K, Rathod PS, Krishnappa S, Nanaiah SP. , et al. Immature teratoma of ovary--outcome following primary and secondary surgery: study of a single institution cohort. Eur J Obstet Gynecol Reprod Biol 2015; 192: 17-21 . Doi: 10.1016/j.ejogrb.2015.06.017
• 28 Aslam MF, Ghayoori R, Khulpateea N. Adnexal masses: relative accuracy of sonography and frozen section in predicting final pathology. J Obstet Gynaecol 2010; 30 (02) 187-189 . Doi: 10.3109/01443610903461444
• 29 Kotsopoulos J, Narod SA. Prophylactic salpingectomy for the prevention of ovarian cancer: who should we target?. Int J Cancer 2020; Feb 9 [ahead of print]
• 30 Kurman R, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34 (03) 433-443 . Doi: 10.1097/PAS.0b013e3181cf3d79
• 31 Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 2011; 42 (07) 918-931 . Doi: 10.1016/j.humpath.2011.03.003
• 32 Diniz PM, Carvalho JP, Baracat EC, Carvalho FM. Fallopian tube origin of supposed ovarian high-grade serous carcinomas. Clinics (Sao Paulo) 2011; 66 (01) 73-76 . Doi: 10.1590/S1807-59322011000100013
• 33 Carvalho JP, Baracat EC, Carvalho FM. Ovarian cancer previvors: how to manage these patients?. Clinics (Sao Paulo) 2019; 74: e1343 . Doi: 10.6061/clinics/2019/e1343
• 34 Urban RR, He H, Alfonso R, Hardesty MM, Gray HJ, Goff BA. Ovarian cancer outcomes: predictors of early death. Gynecol Oncol 2016; 140 (03) 474-480 . Doi: 10.1016/j.ygyno.2015.12.021
• 35 Erickson BK, Martin JY, Shah MM, Straughn Jr JM. Leath CA 3rd. Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center. Gynecol Oncol 2014; 133 (02) 142-146 . Doi: 10.1016/j.ygyno.2014.02.006
• 36 Dahm-Kähler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. Gynecol Oncol 2016; 142 (02) 211-216 . Doi: 10.1016/j.ygyno.2016.05.025
• 37 Casarin J, Laganà AS, Uccella S, Cromi A, Pinelli C, Gisone B. , et al. Surgical treatment of large adnexal masses: a retrospective analysis of 330 consecutive cases. Minim Invasive Ther Allied Technol 2019; Aug 2 [ahead of print]
• 38 Medeiros LRF, Rosa DD, Bozzetti MC, Fachel JMG, Furness S, Garry R. , et al. Laparoscopy versus laparotomy for benign ovarian tumour. Cochrane Database Syst Rev 2009; (002) CD004751 . Doi: 10.1002/14651858.CD004751.pub3
• 39 Ratnavelu ND, Brown AP, Mallett S, Scholten RJPM, Patel A, Founta C. , et al. Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses. Cochrane Database Syst Rev 2016; (003) CD010360 . Doi: 10.1002/14651858.CD010360.pub2